What are our aims, and why?
暂无分享,去创建一个
[1] R. Bruno,et al. Post‐marketing studies of pharmaceutical opioid abuse‐deterrent formulations: a framework for research design and reporting , 2018, Addiction.
[2] Arun S. Hendi,et al. Recent trends in life expectancy across high income countries: retrospective observational study , 2018, British Medical Journal.
[3] M. Livingston,et al. The impact of OxyContin reformulation at the Sydney Medically Supervised Injecting Centre: Pros and cons. , 2018, The International journal on drug policy.
[4] T. Dobbins,et al. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. , 2018, The lancet. Psychiatry.
[5] Sandra C Cortina. Stigmatizing Harm Reduction Through Language: A Case Study Into the Use of “Addict” and Opposition to Supervised Injection Sites in Canada , 2013, Journal of addictions nursing.